Tobacco addiction - PubMed (original) (raw)
Review
Tobacco addiction
Dorothy K Hatsukami et al. Lancet. 2008.
Abstract
Tobacco use is associated with 5 million deaths per year worldwide and is regarded as one of the leading causes of premature death. Comprehensive programmes for tobacco control can substantially reduce the frequency of tobacco use. An important component of a comprehensive programme is the provision of treatment for tobacco addiction. Treatment involves targeting several aspects of addiction including the underlying neurobiology and behavioural processes. Furthermore, building an infrastructure in health systems that encourages and helps with cessation, as well as expansion of the accessibility of treatments, is necessary. Although pharmacological and behavioural treatments are effective in improving cessation success, the rate of relapse to smoking remains high, emphasising the strong addictive nature of nicotine. The future of treatment resides in improvement in patient matching to treatment, combination or novel drugs, and viewing nicotine addiction as a chronic disorder that might need long-term treatment.
Conflict of interest statement
Conflict of interest statements:
Dorothy Hatsukami advised Pfizer on varenicline and was paid an honorarium for the consultation. She also received a grant to conduct nicotine vaccine trials for Nabi Biopharmaceuticals. Lindsay Stead and Prakash Gupta have no conflicts of interests.
Comment in
- Smoking cessation treatment in a public-health context.
Warner KE, Mackay JL. Warner KE, et al. Lancet. 2008 Jun 14;371(9629):1976-8. doi: 10.1016/S0140-6736(08)60846-6. Lancet. 2008. PMID: 18555898 No abstract available. - Smokeless tobacco for cigarette cessation?
Ross GL. Ross GL. Lancet. 2008 Oct 4;372(9645):1217; author reply 1217. doi: 10.1016/S0140-6736(08)61509-3. Lancet. 2008. PMID: 19094946 No abstract available.
Similar articles
- The most addictive drug, the most deadly substance: smoking cessation tactics for the busy clinician.
Crane R. Crane R. Prim Care. 2007 Mar;34(1):117-35. doi: 10.1016/j.pop.2007.02.003. Prim Care. 2007. PMID: 17481990 Review. No abstract available. - Executive summary: nicotine addiction.
Graul AI, Prous JR. Graul AI, et al. Drugs Today (Barc). 2005 Jun;41(6):419-25. doi: 10.1358/dot.2005.41.6.914907. Drugs Today (Barc). 2005. PMID: 16110349 Review. - [European experiences concerning schedules of the fight against the tobacco addiction].
Kurpas D, Steciwko A. Kurpas D, et al. Przegl Lek. 2006;63(10):1123-5. Przegl Lek. 2006. PMID: 17288234 Review. Polish. - Pharmacotherapy for tobacco dependence.
Fant RV, Buchhalter AR, Buchman AC, Henningfield JE. Fant RV, et al. Handb Exp Pharmacol. 2009;(192):487-510. doi: 10.1007/978-3-540-69248-5_17. Handb Exp Pharmacol. 2009. PMID: 19184660 Review. - [Drugs used to treat nicotine addiction].
Zieleń I, Sliwińska-Mossoń M, Milnerowicz H. Zieleń I, et al. Przegl Lek. 2012;69(10):1098-102. Przegl Lek. 2012. PMID: 23421099 Review. Polish.
Cited by
- The Moderating Role of Smoking Amount Per Day on the Relations Between Anxiety Sensitivity, Smoking Dependence, and Cognitive-Affective Aspects of Smoking Among Treatment Seeking Smokers.
Brandt CP, Bakhshaie J, Garey L, Schmidt NB, Leventhal AM, Zvolensky MJ. Brandt CP, et al. Addict Behav Rep. 2015 Jun 1;1:26-33. doi: 10.1016/j.abrep.2015.03.006. Addict Behav Rep. 2015. PMID: 26114159 Free PMC article. - Violation of the Tobacco Control Law by Drivers in Vehicles in Two Streets in İzmir: A Descriptive Study.
Erkoyun E, Alçiçek MS, Selek S. Erkoyun E, et al. Turk Thorac J. 2018 Jul;19(3):132-135. doi: 10.5152/TurkThoracJ.2018.17077. Epub 2018 Jul 1. Turk Thorac J. 2018. PMID: 30083404 Free PMC article. - Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis.
Dhippayom T, Chaiyakunapruk N, Jongchansittho T. Dhippayom T, et al. Drug Saf. 2011 Mar 1;34(3):199-210. doi: 10.2165/11585950-000000000-00000. Drug Saf. 2011. PMID: 21332244 Review. - A testable prognostic model of nicotine dependence.
Ramoni RB, Saccone NL, Hatsukami DK, Bierut LJ, Ramoni MF. Ramoni RB, et al. J Neurogenet. 2009;23(3):283-92. doi: 10.1080/01677060802572911. Epub 2009 Jan 31. J Neurogenet. 2009. PMID: 19184766 Free PMC article. Review. - Validity and reliability of the Korean version of the Wisconsin Smoking Withdrawal Scale.
Joo H, Kang HH, Moon HS, Lee SH. Joo H, et al. Korean J Intern Med. 2021 Jan;36(1):135-144. doi: 10.3904/kjim.2018.355. Epub 2020 Feb 24. Korean J Intern Med. 2021. PMID: 32088942 Free PMC article.
References
- U.S. Department of Health & Human Services. The health consequences of involuntary exposure to tobacco smoke: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.
- U.S. Department of Health & Human Services. The health consequences of smoking: A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
- Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J. 1998;53 (suppl):75–114. - PubMed
- U.S. Department of Health & Human Services. The health consequences of smoking: nicotine and addiction. A report of the surgeon general. USDHHS; 1988. Report No.: DHHS Publication No. (CDC) 88–8406.
- American Psychiatric Association, editor. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: Author; 1994.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical